Status:
COMPLETED
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
Massachusetts General Hospital
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Parkinson Disease
LRRK2
Eligibility:
All Genders
30+ years
Brief Summary
Single site observational study focused on elucidating the genes and biochemical pathways involved in causing Parkinson disease.
Detailed Description
This single site study, is enrolling Parkinson disease (PD) patients and their family members and is limited to participants of Ashkenazi (Eastern European) Jewish descent with GBA and LRRK2 mutations...
Eligibility Criteria
Inclusion
- Parkinson disease patients and their family members and is limited to participants of Ashkenazi (Eastern European) Jewish descent with GBA and LRRK2 mutations, or with 3 or more family members with PD
- Participants must be local to the New York City area and willing to come to Mount Sinai Downtown for annual 2 hour study visits which include obtaining personal medical and family history information, blood, urine and spinal fluid samples, neurological exam and neuropsychiatric testing. Spinal fluid collection is encouraged but optional.
Exclusion
- Patients who do not have Parkinson disease or family members of Ashkenazi (Eastern European) Jewish descent who either has a GBA or LRRK2 mutations OR who has 3 or more family members with PD.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT04668898
Start Date
April 1 2019
End Date
April 1 2025
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai-- Downtown Union Square
New York, New York, United States, 11104